Abstract:Traditional chemotherapy regimens have certain efficacy in the treatment of acute myeloid leukemia (AML), but the treatment of relapsed/refractory AML often results in low response rates, high resistance, and suboptimal therapeutic outcomes. Based on the current state of diagnosis and treatment for relapsed/refractory AML, there is a need for highly efficient and well-tolerated treatment regimens to improve the prognosis of AML patients and provide new choices for AML therapy. This article overviews the efficacy and mechanism of venetoclax in combination with azacitidine and homoharringtonine in the treatment of relapsed/refractory AML.